- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT06702592
Virtual Testis Câncer Leigos Apoio e Sobrevivência Objetivo 2 (VITALSS)
Apoio e sobrevivência virtual ao câncer testicular (estudo VITALSS) Objetivo 2
This study examines how virtual support can enhance well-being and survivorship in men with testicular cancer. Participants in North Carolina will be randomized into two groups: one with access to a virtual support platform and the other with access to patient educational materials only. After six months, the emotional well-being, self-efficacy, financial toxicity, and quality of life of both groups will be compared at 3 months and 6 months after baseline assessments.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Tipo de estudo
Inscrição (Estimado)
Estágio
- Não aplicável
Contactos e Locais
Contato de estudo
- Nome: Deborah S Usinger
- Número de telefone: 919-962-5431
- E-mail: dusinger@email.unc.edu
Estude backup de contato
- Nome: Taylor J Greene
- Número de telefone: 919-962-5506
- E-mail: taylor_greene@med.unc.edu
Locais de estudo
-
-
North Carolina
-
Chapel Hill, North Carolina, Estados Unidos, 27599
- UNC Lineberger Comprehensive Cancer Center
-
Investigador principal:
- Hung-Jui Tan, MD, MSHPM
-
Contato:
- Deborah M Usinger
- Número de telefone: 919-962-0000
- E-mail: dusinger@email.unc.edu
-
Contato:
- Taylor L Greene
- Número de telefone: (919) 962-0000
- E-mail: taylor_greene@med.unc.edu
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Men within 5 years of their initial diagnosis of germ cell testicular cancer.
- The subject is willing and able to comply with study procedures based on the judgment of the investigator.
- Adults aged 18-95 years old.
- Electronic informed consent was obtained to participate in the study.
Exclusion Criteria:
- Woman gender
- Non-English speaking
- Unwilling or unable to complete informed consent.
- On active treatment for another cancer.
- Actively receiving chemotherapy, radiation, or surgery for testicular cancer.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Pesquisa de serviços de saúde
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Virtual support
Participants will have access to the virtual support platform. |
Subjects will use a virtual support platform that was built for their needs. |
|
Outro: Patient educational material
Participants will have access to patient educational material only. |
Participants will have access to patient educational material. |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Emotional well-being scores comparison
Prazo: At baseline, 3-months, and 6-months
|
Emotional well-being will be assessed by patient-reported outcomes questionnaires using a 9-item Positive Affect and Well-Being assessment from the Neuro-QOL Item Bank v1. Emotional well-being scores in virtual support and enhanced usual care will be compared. It is a 5-point Likert scale, higher scores reflect better emotional well-being. |
At baseline, 3-months, and 6-months
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Negative mental health comparison
Prazo: At baseline, 3-months, and 6-months
|
Negative mental health will be assessed by patient-reported outcomes questionnaires using 17 PROMIS items for anxiety, depression, loneliness, and stress. Negative mental health scores in virtual support and enhanced usual care will be compared. Scoring: Each item is rated on a 5-point scale between never (1) to always (5). The responses for each item are summed to get a total raw score. T-Scores: The raw score is then converted to a T-score using a scoring table specific to the PROMIS Anxiety item bank. T-scores standardize the results, making them comparable across different populations and studies. A T-score has a mean of 50 and a standard deviation of 10 in the general population. |
At baseline, 3-months, and 6-months
|
|
Social well-being, acceptance and inclusion comparison
Prazo: At baseline, 3-months, and 6-months
|
Social well-being will be assessed by patient-reported outcomes questionnaires using the 6-item Acceptance/Inclusion subscale of the General Belongingness Scale (GBS). GBS measures an individual's sense of belonging and social connectedness. It consists of 12 items that assess feelings of acceptance and inclusion. Each item is rated on a 7-point Likert scale (1 = Strongly Disagree and 7 = Strongly Agree). Higher scores reflect better inclusion. Scores in virtual support and enhanced usual care will be compared. |
At baseline, 3-months, and 6-months
|
|
Financial Toxicity comparison
Prazo: At baseline, 3-months, and 6-months
|
Financial Toxicity will be assessed by patient-reported outcomes questionnaires using a 12-item Comprehensive Score for Financial Toxicity (COST) instrument. Each item is rated on a 5-point Likert scale 0= = Not at all to 4= Very much. Higher scores indicate higher financial difficulties. Scores in virtual support and enhanced usual care will be compared. |
At baseline, 3-months, and 6-months
|
|
Self-efficacy comparison
Prazo: At baseline, 3-months, and 6-months
|
Self-efficacy will be assessed by patient-reported outcomes questionnaires using 20 PROMIS items for self-efficacy for managing daily activities, emotions, social interactions, and symptoms. Self-efficacy scores in virtual support and enhanced usual care will be compared. Each item is rated on a 5-point scale ( 1 = Never, 5 = Always). Responses are summed to get a total raw score for each domain. Raw scores are converted to T-scores using a scoring table. T-scores standardize results, with a mean of 50 and a standard deviation of 10 in the general population. |
At baseline, 3-months, and 6-months
|
|
Sexual Function and Satisfaction comparison
Prazo: At baseline, 3-months, and 6-months
|
Sexual Function and Satisfaction will be assessed by patient-reported outcomes questionnaires using a 20-item PROMIS SexFS instrument with domains for interest in sexual activity, global satisfaction with sex life, orgasm, and erectile function. Scores in virtual support and enhanced usual care will be compared. Each item is rated on a 5-point Likert scale: 1 = Not at all to 5= Very much. Raw scores are converted to T-scores using a scoring table specific to the PROMIS Sexual Function and Satisfaction profile. T-scores standardize the results, with a mean of 50 and a standard deviation of 10 in the general population.Higher T-scores indicate better sexual function and satisfaction. |
At baseline, 3-months, and 6-months
|
|
Functional well-being comparison Functional well-being comparison
Prazo: At baseline, 3-months, and 6-months
|
Functional well-being will be assessed by patient-reported outcomes questionnaires using a 7-item subscale of the Functional Assessment of Cancer Therapy (FACT-G) instrument. Each item is rated on a 5-point Likert scale, 0= = Not at all to 4= Very much. Higher scores indicate better well-being. Scores in virtual support and enhanced usual care will be compared. |
At baseline, 3-months, and 6-months
|
|
General Quality of Life comparison
Prazo: At baseline, 3-months, and 6-months
|
General Quality of Life will be assessed by patient-reported outcomes questionnaires using the PROMIS Global Health scale is an 8-item, validated survey that represents five core domains (physical function, pain, fatigue, emotional distress, social health). Two items each for physical and mental health as well as a question on quality of life will be administered. Scores in virtual support and enhanced usual care will be compared. Each item is rated on a 5-point Likert scale:1 = Poor to 5 = Excellent. Responses are summed to get a total raw score. The raw score is converted to a T-score using a scoring table. T-scores standardize the results, with a mean of 50 and a standard deviation of 10 in the general population. Higher T-scores indicate better overall health |
At baseline, 3-months, and 6-months
|
|
General Self-Efficacy comparison
Prazo: At baseline, 3-months, and 6-months
|
General Self-Efficacy will be assessed by patient-reported outcomes questionnaires using the 4-item PROMIS instrument that measures the respondent's belief in managing specific problems or issues. Each item is scored on a 5-point Likert scale, 1 = Never to 5 = Always. The raw score is then converted to a T-score using a scoring table specific to the PROMIS domain being measured. T-scores standardize the results, with a mean of 50 and a standard deviation of 10 in the general population. Higher T-scores indicate more of the concept being measured Scores in virtual support and enhanced usual care will be compared. |
At baseline, 3-months, and 6-months
|
|
Virtual platform usage
Prazo: At baseline, 3-months, and 6-months
|
Virtual platform usage will be assessed by time, visits, scrolling, posts, and messages spent on the virtual platform. |
At baseline, 3-months, and 6-months
|
|
Healthcare and supportive care utilization
Prazo: At baseline, 3-months, and 6-months
|
Self-reported use of healthcare and supportive care services will be assessed by a survey. Participants will be asked to quantify healthcare or other supportive care visits over the intervention period. |
At baseline, 3-months, and 6-months
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Hung-Jui Tan, MD, UNC Lineberger Comprehensive Cancer Center
Publicações e links úteis
Links úteis
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Estimado)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
- Doenças urogenitais
- Doenças Genitais
- Doenças do Sistema Endócrino
- Neoplasias Genitais Masculinas
- Neoplasias urogenitais
- Neoplasias por local
- Neoplasias
- Doenças Genitais, Masculino
- Doenças Urogenitais Masculinas
- Sintomas Comportamentais
- Neoplasias das Glândulas Endócrinas
- Distúrbios Gonadais
- Estresse, Psicológico
- Doenças testiculares
- Comportamento
- Estresse financeiro
- Neoplasias testiculares
Outros números de identificação do estudo
- LCCC2418 AIM2
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .